セロトニン再吸収抑制剤と心筋梗塞の選択性
W H Sauer1, J A Berlin, S E Kimmel
1Cardiovascular Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Circulation
|October 17, 2001
まとめ
選択的セロトニン再吸収阻害剤 (SSRI) は,心筋梗塞 (MI) に対して保護することがあります. この研究では,SSRIの使用は,喫煙者における最初のMIのリスクが著しく低下することが判明し,これは血小板活性化への影響による可能性がある.
科学分野:
- 心臓病学 心臓病学
- 精神科医は精神病を患っている.
- 薬理学 薬理学とは
背景:
- うつ病は,心筋梗塞 (MI) の既知の危険因子です.
- セロトニン再吸収抑制剤 (SSRI) は,一般的に処方される抗うつ剤です.
- SSRIは,セロトニン媒介の血小板活性化を低下させることで,MIのリスクを軽減する可能性があります.
研究 の 目的:
- SSRI使用と第1回心筋梗塞のリスクとの関連を調査する.
- 鬱病の治療を超えて,SSRIの潜在的心臓保護効果を探求する.
主な方法:
- 653人の初発性心筋梗塞の症例と2990人の対照群を対象に,症例対照研究が行われました.
- 参加者は,8郡の地域から30~65歳の喫煙者でした.
- 抗うつ薬の使用およびその他の危険因子に関するデータは,電話インタビューを通じて収集され,多変数ロジスティック回帰を使用して分析されました.
主要な成果:
- 現在のSSRI使用者は,使用しない人と比較して,最初のMI (0.35) の確率比が著しく低い.
- 非SSRI抗うつ剤使用者は,心筋梗塞のリスクを減らすという非有意な傾向を示しました.
- SSRIと心筋梗塞リスクの低下との関連は,複数の混同要因を調整した後も依然として有意であった.
結論:
- SSRIの使用は,心筋梗塞に対する保護効果を与える可能性があります.
- この保護効果は,セロトニン媒介の血小板活性化に対するSSRIの抑制と関連している可能性がある.
- また,SSRIは,心筋梗塞の危険に寄与するうつ病に関連する他の要因を改善する可能性があります.
さらに関連する動画
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
4.0K
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.9K
関連する概念動画
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.9K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.9K
01:25Antidepressant Drugs: Overview
2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
01:23Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
01:28Acute Coronary Syndrome IV: Interprofessional Care
525
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
525